Areas of Expertise:
Bleeding and clotting disorders, Sickle cell disease, General hematology
Areas of Expertise:
Bleeding and clotting disorders, Sickle cell disease, General hematology
Benjamin J. Samelson-Jones, MD, PhD, is an attending physician in the Division of Hematology at Children's Hospital of Philadelphia. He is board certified in hematology/oncology and pediatrics. He specializes in treating children with bleeding or clotting disorders, sickle cell disease, and other blood disorders. His current research is focused on gene therapy and immune responses related to Hemophilia.
Dr. Samelson-Jones enjoys this specialty because of the ability to provide care on an ongoing basis throughout childhood. Those long-term relationships are rewarding for both doctor and patient and a key part of CHOP’s culture of care. “I want every family who comes to CHOP to leave feeling that their child received personalized, high-quality, holistic medical care,” said Dr. Samelson-Jones.
Dr. Samelson-Jones earned his medical degree as well as a PhD rom Albert Einstein College of Medicine, Bronx, New York. He continued his training with a residency in pediatrics at Children’s National Health System in Washington, DC and a fellowship in hematology/oncology at CHOP.
Dr. Samelson-Jones is excited about the advances being made in curative therapies for inherited blood disorders. His research is also focused in that area, including projects to investigate the molecular basis of coagulation and immune responses in hemophilia as well as a potential gene therapy for hemophilia.
MD - Albert Einstein College of Medicine, Bronx, NY
Pediatrics - Children’s National Health System, Washington, DC
Hematology/Oncology - The Children’s Hospital of Philadelphia, Philadelphia, PA
PhD - Albert Einstein College of Medicine, Bronx, NY
MS - Albert Einstein College of Medicine, Bronx, NY
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
French RA, Samelson-Jones B., Niemeyer GP, Lothrop CD Jr, Merricks EP, Nichols TC, Arruda VR. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv. 2018 Mar 13;2(5):505-508.
Samelson-Jones B., Kramer PM, Chicka M, Gunning III WT, Lambert MP: MYH9-macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia. Pediatric Blood and Cancer 2018.
Arruda VR, Doshi BS, Samelson-Jones B Emerging therapies for hemophilia: controversies and unanswered questions. F1000 Research 2018.
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones B., Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine 377(23): 2215-2227, 2017.
Arruda VR, Doshi BS, Samelson-Jones B. Novel approaches to hemophilia therapy: successes and challenges. Blood 130(21): 2251-2256, 2017.
Herrmann A, Samelson-Jones B., Brake S, Samelson R.: IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology Reports 7: e197-e200, 2017.
Siner, J.I.*, and Samelson-Jones, B.*, Crudele, J.M., French, R.A., Lee, B.J., Zhou, S., Merricks, E., Raymer, R., Nichols, T., Camire R. M., Arruda V. R. (2016) Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. Journal Clinical Investigation Insight: 16: e89371. (*contributed equally to work)
Arruda, V.R. and Samelson-Jones, B. (2016) Gene Therapy for Hemophilia with Inhibitors. Journal of Thrombosis and Haemostasis 14(6): 1121.
Arruda, V.R. and Samelson-Jones, B. (2015) Obstacles and future of gene therapy for hemophilia. Expert Opinion on Orphan Drugs 3:997-1010.
Samelson-Jones B., Yeh S.R. (2006) Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 45:8527-8538.
Wu Z., Jakes K.S., Samelson-Jones B., Lai B., Zhao G., London E., Finkelstein A. (2006) Protein translocation by bacterial toxin channels: a comparison of diphtheria toxin and colicin Ia. Biophys J. 91:3249-3256.
Baluschev S., Friedman N., Khaykovich L., Carasso D., Johns B.*, and Davidson N. (2000) Tunable and frequency stabilized diode-laser with Doppler-free two-photon Zeeman lock. Applied Optics 39: 4970-4974. (* The correct spelling should be Samelson-Jones B.)
George LA, Ragni MV, Samelson-Jones B, Cuker A, Runoski AR, Cole G, Wright F, Chen Y, Hui DJ, Wachtel K, Takefman D, Couto LB, Reape KZ, Carr ME, Anguela XM, High KA: Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a. Blood 130: 604, 2017.
George LA, Sullivan SK, Giermasz A, Samelson-Jones B, Ducore JM, Teitel JM, Cuker A, Von Mackensen S, Majumdar S, McGuinn CE, Runoski AR, Wright F, Dasen S, Barber K, Chen Y, Hui DJ, Patel R, Liu Y, Wachtel K, Takefman D, Couto LB, Reape KZ, Carr CE, Anguela XM, High KA : Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B - 1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence. Blood 2017 130:601 130: 601, 2017.
Hui DJ, Liu Y, Patel R, Chen Y, George LA, Sullivan SK, Giermasz A, Rasko J, Samelson-Jones B, Ducore JM, Dasen S, Carr ME, Anguela XM, High KA: Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Factor IX with Minimal Immune Response. Blood 130: 2056, 2017.
Parsons NA, Ho MD, Davidson RJ, Thalji NK, Samelson-Jones B, Camire RM, George LA: Regulation of Factor VIII By Activated Protein C: Assessment In Vitro and In Vivo. Blood 130: 3650, 2017.
Samelson-Jones B, French RA, Crudele JM, Nichols TC, Arruda VR: The Role of Transgene Levels in Immune Tolerance Induction after AAV Gene Therapy in Hemophilia B Canine Models. Blood 130: 2057, 2017.
George, L.A., Sullivan, S.K., Giermasz, A, Ducore, J. M, Teitel, J.M., Samelson-Jones, B., Cuker, A, Sullivan, L.M., Majumdar, S., McGuinn, C.E., Galvao, A.M., Luk A.Y., Wright, J.F., Chen, Y., Hui, D.J., Wachtel, K., Galas, T., Takefman, D., Couto, L.B., Carr, M.E., Anguela, X.M., High, K.A. (April 2017) Initiation of Oral Steroid Therapy Produced Rapid Normalization of Transaminase Levels and Stabilization of FIX Activity in Subjects Who Developed Capsid Directed T-Cell Responses in the SPK-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Phase 1/2 Trial. Hemostasis and Thrombosis Research (HTRS) Annual Meeting. Scottsdale, AZ.
Samelson-Jones B., Finn J. D., Camire R. M., Arruda V. R., (December 2016) New Hyperactive Factor IX Variants Bioengineered Based Upon Biochemical Studies of Factor IX Padua. American Society of Hematology (ASH) Annual Meeting, San Diego, CA.
Samelson-Jones B., Finn J. D., Raffini, L., Camire R. M., Arruda V. R. (June 2015) Investigations into Anticoagulant Resistance and Enhanced Activation as Putative Molecular Mechanisms of the Hyperactivity of Factor IX Padua. Congress of the International Society on Thrombosis and Haemostasis Congress (ISTH). Toronto, Canada
Samelson-Jones, B., French R.A., Martin N.B., Nichols T.C., Camire R.M., Arruda V.R. (July 2017) Immunogenicity and efficacy of FIX-Padua in distinct canine models of severe hemophilia B following AAV gene therapy to skeletal muscle or liver. Congress of the International Society on Thrombosis and Haemostasis (ISTH). Berlin, Germany
Samelson-Jones B., Siner J.I., Daniel, T.V. Arruda, V.R. (July 2017) New Implications of the Deleterious Role of Furin Processing on Factor VIII Biology. Congress of the International Society on Thrombosis and Haemostasis (ISTH). Berlin, Germany.
Samelson-Jones B., Finn J. D., Camire R. M., Arruda V. R., (November 2016) Rationally Designed Hyperactive Factor IX Variants Based Upon Biochemical Studies of Factor IX Padua. 45rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis, Philadelphia, PA.
Siner, J.I., Samelson-Jones, B., Crudele, J.M., French, R.A., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (April 2016) Enhanced Hemophilia A Gene and Protein Therapy Using a Novel PACE/Furin Escaping Factor VIII Variant. Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL.
Siner, J.I., Samelson-Jones, B., Crudele, J.M., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (November 2015) A Novel Furin-Evading Factor VIII Variant That Enhances Hemophilia A Therapy. 44rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis, Philadelphia, PA.
Siner, J.I., Samelson-Jones, B., Crudele, J.M., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (June 2015) Enhanced Factor VIII Gene Therapy for Hemophilia A Dogs with a Novel Furin-Evading Factor VIII Variant. Congress of the International Society on Thrombosis and Haemostasis Congress (ISTH). Toronto, Canada
2018, Outstanding Poster Presentation Award, American Society of Gene and Cell Therapy
2015, Children’s Hospital of Philadelphia (CHOP) Research Poster Day Prize
2014, Thrombosis-Hemostasis Summit of North America (THSNA) Travel Award
2011, Medical Student Teaching Award
2006, Society of Porphyrins and Phthalocyanines Student Assistance Grant
2006, MS with distinction, Albert Einstein College of Medicine, Bronx, NY
2001, summa cum laude, Amherst College, Amherst, MA
2001, The William Warren Stifler Physics Prize
2000, Dean of Faculty Fellowship for Student Research
1999, The Basset Physics Prize
Public Library of Science (PLOS) One
Pediatric Blood and Cancer
Journal of Haemostasis and Thrombosis
European Oncology & Haematology
Faculty of 1,000
Phi Beta Kappa
American Academy of Pediatrics
American Society of Hematology
American Society of Pediatric Hematology and Oncology
Hemostasis and Thrombosis Research Society
International Society of Thrombosis and Haemostasis
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.